Federal Judge Upholds UTC's Remodulin Patent Against Sandoz ANDA

Drug Industry Daily
A A
Sandoz must wait until a patent on United Therapeutics Corporation’s pulmonary arterial hypertension drug Remodulin expires in 2017 before it can market a generic version.

To View This Article:

Login

Subscribe To Drug Industry Daily